Adjuvant immunotherapy with high-dose ipilimumab has led to improvements in overall survival, whereas therapy with nivolumab and pembrolizumab has improved relapse-free survival with greater safety. Furthermore, adjuvant-targeted therapy with dabrafenib and trametinib has improved survival outcomes in BRAFV...
Current Oncology Reports (2024) 26:735–743 https://doi.org/10.1007/s11912-024-01539-0 REVIEW Axillary Management: How Much Is Too Much? Nicci Owusu‑Brackett1 · Benjin Facer2 · Dionisia Quiroga3 · Ashley Pariser3 · Michael Grimm4 · Sasha Beyer2 · ...
Stunning advances in gene research and data mining will predict diseases and devise treatments tailored to each of us.
Lenvatinib + pembrolizumab Nivolumab + ipilimumab Single-agent TKI OtherVote DISCUSSION QUESTIONS To what extent is risk status a deciding factor in your first-line treatment decision making? What drives your selection of first-line therapy for favorable-risk, metastatic ccRCC? Thai H. Ho,...
Pembrolizumab (Keytruda) This medicine is a checkpoint inhibitor used for high-risk, early-stage, triple-negative breast cancer (TNBC). It's done along with chemotherapy. It can also be given to treat metastatic TNBC when the tumor makes PD-L1 protein. ...
(3) how much do pathologists trust and accept AI? and (4) what is the best practical scoring scheme for PD-L1 expression in breast cancer? What is AI’s role in PD-L1 expression assessment? Human pathologists are not good at precisely evaluating ratios, especially when hundreds of cells ...
Immunotherapy is another game-changer in skin cancer treatment. This approach uses the power of the immune system to recognize and attack cancer cells. Drugs known as immune checkpoint inhibitors, like pembrolizumab and nivolumab, have shown remarkable results in treating melanoma by blocking proteins ...
they based how much treatment they gave on the patient’s MRD status. So, if any patient were MRD negative 2 times— so let’s say they’re MRD negative after induction and then after transplant—they could stop treatment and be observed, which these patients were called MRD...
immunization with live avirulent deficiency has not yet been identified in humans, it seems likely that the phenotype will be much more complex and profound than that of the FcR deficiency described here, because the human FcR is expressed by additional cell types, namely T and NK cells (...
There is a clear and urgent necessity to lower cancer drug prices to keep lifesaving drugs available and affordable for patients. As one patient advocate recently put it: “Innovation is meaningless if nobody can afford it.” Lack of Effective Solutions Much has been written about the reasons ...